

**TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS**

**Name of the Issue:** Jupiter Life Line Hospitals Limited

- 1. Type of Issue (IPO/FPO)** IPO
- 2. Issue Size (Rs. Cr)** INR 869.07 Cr
- 3. Grade of issue along with name of the rating agency**
- Name** NA
- Grade** NA
- 4. Subscription Level (Number of times)** 65.44 (excluding the Anchor Investor Portion )

Source: Minutes of the Meeting held for the approval and finalization of the Basis of Allotment dated September 13, 2023

**5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges**

Particulars	Percentage
(i) allotment in the issue	13.50%*
(ii) at the end of the 1st Quarter immediately after the listing of the issue	20.76%*
(iii) at the end of 1st FY (March 31, 2024)#	21.75%
(iv) at the end of 2nd FY (March 31, 2025)^	NA
(v) at the end of 3rd FY (March 31, 2026)^	NA

(\*) As per the shareholding pattern as on the date of listing.

\* As per the shareholding pattern as on September 30, 2023

# As per the shareholding pattern as on March 31, 2024

(^ ) QIB Holding not disclosed as reporting for relevant period / fiscal years has not been completed

**6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)**

Consolidated	(Rs in Crores)		
Parameters	1st FY (March 31, 2024)#	2nd FY (March 31, 2025)*	3rd FY (March 31, 2026)*
Income from operations	1069.50	N.A.	N.A.
Net Profit for the period	176.61	N.A.	N.A.
Paid-up equity share capital	65.57	N.A.	N.A.
Reserves excluding revaluation reserves	1103.17	N.A.	N.A.

\* Financials not disclosed as reporting for the relevant fiscal years has not been completed.

# Source : Audited Financial Statements for the financial year 2023-24 submitted to Stock Exchange

## 7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on the National Stock Exchange of India Limited and the BSE Limited .

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)*	N.A.
(iii) at the end of 3rd FY (March 31, 2026)*	N.A.

\* Trading status not disclosed as reporting for the relevant fiscal years has not been completed

## 8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	Nil	Nil
(ii) at the end of 2nd FY (March 31, 2025)*	N.A.	N.A.
(iii) at the end of 3rd FY (March 31, 2026)*	N.A.	N.A.

\*Changes in directors not disclosed as reporting for relevant fiscal years has not been completed.

For FY 2025, following changes in directors has taken place till November 15, 2024.

Appointment of Mr. Amar Manjrekar (DIN: 00463989) as Additional Director in the capacity of Non- Executive Independent Director of the Company for a period of five years, with effect from August 09, 2024,

## 9. Status of implementation of project/ commencement of commercial production

- (i) As disclosed in the offer document: NA
- (ii) Actual implementation: NA
- (iii) Reasons for delay in implementation, if any: NA

## 10. Status of utilization of issue proceeds

### (i) As disclosed in the offer document:

The Company proposes to utilize the Net Proceeds towards funding the following objects:

(in ₹ million)

Sr. No.	Particulars	Amount to be funded from the Net Proceeds	Estimated schedule of deployment of Net Proceeds in Fiscal 2024
1	Repayment/pre-payment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	5,101.55
2	General Corporate Purpose	11.63	11.63
<b>Total</b>		<b>5,113.18</b>	<b>5,113.18</b>

### (ii) Actual utilization:

(Rs in million)

Item Head	Amount as proposed in the Offer Document	Amount utilized			Total unutilized amount
		As at beginning of the quarter	During the quarter	At the end of the quarter	
Repayment/prepayment, in full or part, of borrowings availed from banks by the Company and Material Subsidiary	5,101.55	5,101.55	Nil	5,101.55	Nil
General Corporate Purposes (GCP)	11.63	11.63	Nil	11.63	Nil
<b>Total</b>	<b>5,113.18</b>	<b>5,113.18</b>	<b>Nil</b>	<b>5,113.18</b>	<b>Nil</b>

Source : Monitoring Agency Report dated May 10, 2024 for the quarter ended March 31, 2024.

### (iii) Reasons for deviation, if any: Nil

## 11. Comments of monitoring agency, if applicable

(a) Comments on use of funds	Nil
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	None
(c) Any other reservations expressed by the monitoring agency about the end use of funds	None

Source : Monitoring Agency Report dated May 10, 2024 for the quarter ended March 31, 2024.

## 12. Pricing Data

<b>Issue Price (Rs.):</b>	735/-
<b>Designated Stock Exchange:</b>	NSE
<b>Listing Date:</b>	September 18, 2023

Price parameters	At close of listing day (i.e. September 18, 2023)	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day #	As at the end of 1st FY after the listing of the issue (March 31, 2024)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	1,075.75	1045.65	1,150.60	1196.5	1653.95	970.00
NIFTY 50	20,133.30	19811.5	21,456.65	22326.90	22526.60	17312.75
Sectoral Index	NA	NA	NA	NA	NA	NA

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2025)*			As at the end of 3rd FY after the listing of the issue (March 31, 2026)*		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (NSE)	NA	NA	NA	NA	NA	NA
NIFTY 50	NA	NA	NA	NA	NA	NA
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: NSE website

\* Pricing Data not disclosed as reporting for the relevant fiscal years has not been completed  
# 90<sup>th</sup> Day being 16<sup>th</sup> December, 2023 i.e Saturday, hence the data has been taken of previous working day Friday i.e. 15<sup>th</sup> December, 2023

13. **Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)**

Accounting ratio		As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2024) <sup>(3)</sup>	At the end of 2nd FY (March 31, 2025) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2026) <sup>(2)</sup>
EPS	<b>Issuer:</b>	--	--	--	--
	Consolidated (Basic)	13.95	28.65	N.A	N.A
	Consolidated (Diluted)	12.95	28.65	N.A	N.A
	Peer Group :	--	--	--	--
	Apollo Hospitals Enterprise Limited	Basic – 56.97 Diluted – 56.97	Basic – 62.50 Diluted – 62.50	N.A	N.A
	Fortis Healthcare Limited	Basic – 7.80 Diluted – 7.80	Basic – 7.93 Diluted – 7.93	N.A	N.A
	Max Healthcare Institute Limited	Basic – 11.38 Diluted – 11.36	Basic – 10.89 Diluted – 10.84	N.A	N.A
	Narayana Hrudayalaya Limited	Basic – 29.85 Diluted – 29.85	Basic – 38.86 Diluted – 38.86	N.A	N.A
	Global Health Limited	Basic – 12.58 Diluted – 12.57	Basic – 17.80 Diluted – 17.80	N.A	N.A
	Krishna Institute of Medical Sciences Limited	Basic – 42.03 Diluted – 42.03	Basic – 38.75 Diluted – 38.75	N.A	N.A

	Industry Avg:	NA	N.A	N.A	N.A
P/E	<b>Issuer:</b>	--	--	--	--
	Consolidated (Basic)	56.76	41.81	N.A	N.A
	Consolidated (Diluted)	56.76	41.81	N.A	N.A
	Peer Group <sup>1</sup>	--	--	--	--
	Apollo Hospitals Enterprise Limited	Basic – 84.64 Diluted – 84.64	Basic – 101.63 Diluted – 101.63	N.A	N.A
	Fortis Healthcare Limited	Basic – 40.26 Diluted – 40.26	Basic – 52.95 Diluted – 52.95	N.A	N.A
	Max Healthcare Institute Limited	Basic – 45.97 Diluted – 45.97	Basic – 75.34 Diluted – 75.68	N.A	N.A
	Narayana Hrudayalaya Limited	Basic – 33.14 Diluted – 33.14	Basic – 32.95 Diluted – 32.95	N.A	N.A
	Global Health Limited	Basic – 53.70 Diluted – 53.70	Basic – 74.37 Diluted – 74.37	N.A	N.A
	Krishna Institute of Medical Sciences Limited	Basic – 45.09 Diluted – 45.09	Basic – 53.11 Diluted – 53.11	N.A	N.A
	Industry Composite:	50.47	N.A	N.A	N.A
RoNW (%)	<b>Issuer:</b>	--	--	--	--
	Consolidated	20.03	15.11	N.A	N.A
	Peer Group:	--	--	--	--

	Apollo Hospitals Enterprise Limited	16.40	13.50	N.A	N.A
	Fortis Healthcare Limited	20.90	8.42	N.A	N.A
	Max Healthcare Institute Limited	62.80	12.58	N.A	N.A
	Narayana Hrudayalaya Limited	35.40	27.38	N.A	N.A
	Global Health Limited	16.20	16.45	N.A	N.A
	Krishna Institute of Medical Sciences Limited	25.70	18.38	N.A	N.A
	Industry Composite:	NA	N.A	N.A	N.A
NAV	<b>Issuer:</b>	--	--	--	--
	Consolidated	64.39	178.24	N.A	N.A
	Peer Group:	--	--	--	--
	Apollo Hospitals Enterprise Limited	378.33	481.75	N.A	N.A
	Fortis Healthcare Limited	46.67	101.50	N.A	N.A
	Max Healthcare Institute Limited	24.14	86.51	N.A	N.A
	Narayana Hrudayalaya Limited	90.50	141.11	N.A	N.A
	Global Health Limited	90.35	108.22	N.A	N.A

	Krishna Institute of Medical Sciences Limited	193.96	228.46	N.A	N.A
	Industry Avg:	NA	N.A	N.A	N.A

**Notes:**

- (1) Prospectus dated September 11, 2023.
- (2) Not disclosed as the reporting for the relevant fiscal years has not been completed.
- (3) Source : Audited Financial Statements for the financial year 2023-24.

**14. Any other material information**

Particulars		Date											
The Company has informed that one of the object for raising funds from the public was to settle the borrowings obtained from banks by Jupiter Life Line Hospitals Limited ('The Company') and Jupiter Hospital Project Private Limited ('The Material Subsidiary'). The Company and its Material Subsidiary have repaid the proposed borrowed amount from the Banks i.e., ₹ 3464.50 million, while the Material Subsidiary has repaid ₹ 1637.05 million, respectively.		06-Oct- 2023											
The Company has informed about the resignation of M/s. Gala & Associates., Chartered Accountants as Internal Auditor of the Company effective from February 9, 2024.		09-Feb-2024											
The Company has informed about the appointment of M/s. G. M. Kapadia & Co., Chartered Accountants as Internal Auditor of the Company for the financial year 2023-24.		09-Feb-2024											
The Company has informed about the acquisition of land for setting up hospital on lease of 10 years with an annual lease rental of Rs.9.27 Crores at Bibvewadi, Pune, with an area of ~11,500 Sq. Meter		22-Feb-2024											
The Company has informed about the assigning of ratings on bank facilities as follows :		27-March-2024											
<table border="1"> <thead> <tr> <th>Name of Agency</th> <th>Credit Facilities</th> <th>Assigned Rating</th> <th>Remark</th> </tr> </thead> <tbody> <tr> <td rowspan="2">ICRA Limited</td> <td>Long term Scale</td> <td>[ICRA] A+ (Stable)</td> <td>Upgraded from [ICRA] A (Stable)</td> </tr> <tr> <td>Short term Scale</td> <td>[ICRA] A1</td> <td>Upgraded from [ICRA] A2+</td> </tr> </tbody> </table>		Name of Agency	Credit Facilities	Assigned Rating	Remark	ICRA Limited	Long term Scale	[ICRA] A+ (Stable)	Upgraded from [ICRA] A (Stable)	Short term Scale	[ICRA] A1	Upgraded from [ICRA] A2+	
Name of Agency	Credit Facilities	Assigned Rating	Remark										
ICRA Limited	Long term Scale	[ICRA] A+ (Stable)	Upgraded from [ICRA] A (Stable)										
	Short term Scale	[ICRA] A1	Upgraded from [ICRA] A2+										
The Company has informed about the approval of board for addition of 75 beds capacity in the existing Indore Hospital and 22 beds capacity in the existing Pune Hospital		10-May-2024.											
The Company has informed about the appointment of M/s. Yogesh Sharma & Co, as the Secretarial Auditor of the Company for financial year 2024-25		10-May-2024.											
The Company has informed about the appointment of M/s. V. J. Talati & Co as the Cost Auditor of the Company for financial year 2024-25		10-May-2024											
The Company has informed about the resignation of M/s. B. Mantri & Co., Chartered Accountants (Firm Registration No.: 013559C), the statutory auditor of its Material Subsidiary i.e. Jupiter Hospital Projects Private Limited which will take effect on submission of Limited Review Report for the quarter ended on June 30, 2024.		01-August-2024											
The Company has informed about the appointment of M/s. Varma & Varma, Chartered Accountants, as the Internal Auditor of the Company for financial year 2024- 25.		09-August-2024											
The Company has informed about the appointment of M/s. Shah Valera & Associates LLP as the Statutory Auditor of its material subsidiary namely Jupiter Hospital Projects Private Limited for the term of 5 years from the conclusion of this		06-September-2024											



13th Annual General Meeting until the conclusion of the 18th Annual General Meeting to be held in the year 2029.	
The Company has informed about the change in the designation of Mr. Sumit Goda (Senior Management Personnel), from Corporate Head – Supply Chain & Central Purchase Unit to Chief Commercial Officer of the Company with effective from September 14, 2024.	14-September-2024

Source- Stock Exchange Filings

All the above information has been updated till November 15, 2024, unless indicated otherwise

NUVAMA